News summary

Commit Biologics announces final close of $60 million seed financing to advance complement-powered immune engagers toward the clinic

Source: BioSpace - Funding • Published: 17 Nov 2026, 09:36

Summarized by Masters of Longevity from BioSpace - Funding.

Commit closed $60 million to fund IND-enabling work and clinic entry.

Commit Biologics announces final close of $60 million seed financing to advance complement-powered immune engagers toward the clinic
Key Takeaways
  • Commit closed $60 million seed financing led by Ackermans & van Haaren.
  • Proceeds will fund IND-enabling activities and an IND filing.
  • COM002 is a dual-targeting BiCE for cancer and autoimmune indications.
Read the full article at BioSpace - Funding ↗

Continue exploring

Recommended MoL Picks

MoL PickCreatine and Cancer: Why New Mouse Studies Point in Opposite DirectionsCreatine strengthened antitumour immune cells in one mouse study—and promoted metastasis through platelets in another. The apparent contradiction reveals why neither result is a supplement recommendation.MoL PickLongevity is leaving the clinicStephen Watson argues that hotels, gyms and residential communities can build longevity memberships around the relationships they already have.MoL PickSeed Oils and Health: Inflammation, Processing and EvidenceHuman trials, processing risks and long-term health ask different questions. What can seed-oil research tell us—and what remains unresolved?